Effect of supplementation in treatment of polycystic ovary syndrome

Effects of folic acid supplementation on nitric oxide, factors of lipid peroxidation and biomarkers of oxidative stress in overweight and obese women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201311205623N12

Enrollment

Registered

2013-12-01

Start date

2013-11-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention group: Folic acid tablet, 1 mg, daily, for 8 weeks orally. Intervention 2: Intervention group: Folic acid tablet, 5 mg, daily, for 8 weeks orally. Intervention 3: Control

Treatment - Drugs

Intervention group: Folic acid tablet, 1 mg, daily, for 8 weeks orally.

Intervention group: Folic acid tablet, 5 mg, daily, for 8 weeks orally.

Control group: Placebo tablet, daily, for 8 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Women aged 18-35 years; diagnosed with PCOS. Exclusion Criteria: Individuals with neoplastic; cardiovascular disorders; malabsorptive disorders; current or previous (within the last 6 months) use of hormonal; antidiabetic medications; anti-obesity medications.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Catalase. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Catalase. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026